Oxford–AstraZeneca COVID-19 vaccine

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222,^[5] and sold under the brand name Covishield and Vaxzevria among others,^[19][20] is a viral vector vaccine for COVID-19 developed by Oxford University and AstraZeneca given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1.^{[21][22][23][24]} An analysis published on 19 February 2021 showed an efficacy of 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, increasing to 81.3% when the second dose is given 12 weeks or more after the first.^[25]

Oxford–AstraZeneca COVID-19 vaccine

Box containing 100 COVID-19 Vaccine AstraZeneca doses
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Trade names	Vaxzevria,[1] Covishield[2][3]
Other names	AZD1222,[4][5] ChAdOx1 nCoV-19,[6] ChAdOx1-S,[7] COVID-19 Vaccine AstraZeneca,[8][9] AstraZeneca COVID-19 Vaccine,[10]
License data	EU EMA: by INN US DailyMed: AstraZeneca_COVID-19_Vaccine
Pregnancy category	AU: B2[7][8]
Routes of administration	Intramuscular
ATC code	None
Legal status
Legal status	AU: S4 (Prescription only) [7] CA: Schedule D; Authorized by interim order [10][11] UK: Conditional and temporary authorisation to supply [9][12] EU: Conditional marketing authorisation [1][13][14] KR, BR – Approved[15][16] IND, INA,[17] BD, AG, SV, DOM, TU,MEX, NE, SL, SRB:[18] Emergency Authorization only